Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer

被引：6

作者：

Kodama, Hirotake ^{[1
]}

Hatakeyama, Shingo ^{[1
]}

Narita, Shintaro ^{[2
]}

Takahashi, Masahiro ^{[3
]}

Sakurai, Toshihiko ^{[4
]}

Kawamura, Sadafumi ^{[5
]}

Hoshi, Senji ^{[6
]}

Ishida, Masanori ^{[7
]}

Kawaguchi, Toshiaki ^{[8
]}

Ishidoya, Shigeto ^{[9
]}

Shimoda, Jiro ^{[7
]}

Narita, Takuma ^{[1
]}

Sato, Hiromi ^{[2
]}

Mitsuzuka, Koji ^{[3
]}

Tochigi, Tatsuo ^{[5
]}

Tsuchiya, Norihiko ^{[4
]}

Arai, Yoichi ^{[5
]}

Habuchi, Tomonori ^{[2
]}

Ohyama, Chikara ^{[1
]}

机构：

[1] Hirosaki Univ, Dept Urol, Sch Med, Hirosaki, Aomori, Japan

[2] Akita Univ, Dept Urol, Sch Med, Akita, Japan

[3] Tohoku Univ, Dept Urol, Sch Med, Aoba Ku, Sendai, Miyagi, Japan

[4] Yamagata Univ, Dept Urol, Sch Med, Yamagata, Japan

[5] Miyagi Canc Ctr, Dept Urol, Natori, Miyagi, Japan

[6] Yamagata Prefectural Cent Hosp, Dept Urol, Yamagata, Japan

[7] Iwate Prefectural Isawa Hosp, Dept Urol, Mizusawa Ku, Oshu, Iwate, Japan

[8] Aomori Prefectural Cent Hosp, Dept Urol, Aomori, Japan

[9] Sendai City Hosp, Dept Urol, Taihaku Ku, Sendai, Miyagi, Japan

来源：

CLINICAL GENITOURINARY CANCER | 2019年 / 17卷 / 06期

基金：

日本学术振兴会;

关键词：

Castration-resistant prostate cancer; Prostate cancer; PSA; Sequential therapy; Survival; ANDROGEN DEPRIVATION; CHEMOTHERAPY; THERAPY;

D O I：

10.1016/j.clgc.2019.05.029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigate the effect of low prostate-specific antigen (PSA) on prognosis in 575 patients with metastatic castration-naive prostate cancer. The overall survival after castration-resistant prostate cancer diagnosis was significantly shorter in the PSA < 100 group than in the PSA >= 100 group. PSA < 100 ng/mL might be a poor prognostic factor in patients with metastatic castration-naive prostate cancer after castration-resistant prostate cancer. Introduction: This study aimed to investigate the effect of low prostate-specific antigen (PSA) on prognosis, as the association of initial PSA level with prognosis in patients with metastatic castration-naive prostate cancer (mCNPC) remains unclear. Patients and Methods: We evaluated 575 patients with mCNPC from 10 hospitals. Patients were stratified into 2 groups according to their initial PSA: PSA < 100 and PSA >= 100 groups. We compared castration-resistant prostate cancer (CRPC)-free survival, overall survival (OS), and OS from the CRPC diagnosis between the groups. Multivariate Cox regression analysis was performed to evaluate the effect of initial PSA level on prognosis. Results: Of the 575 patients, 196 (34%) patients belonged to the PSA < 100 group. No significant difference was found in patients' backgrounds except for PSA, the extent of disease, and high tumor burden between the groups. CRPC-free survival was significantly shorter in the PSA >= 100 group than in the PSA < 100 group. However, the OS after CRPC diagnosis was significantly shorter in the PSA < 100 group than that of the PSA >= 100 group. Multivariate analyses showed that PSA < 100 ng/mL was an independent factor for OS after CRPC, whereas no significant association was observed in the CRPC-free survival and OS. Conclusions: A significant effect of initial PSA < 100 ng/mL on OS after CRPC was observed. PSA < 100 ng/mL might be a poor prognostic factor in patients with mCNPC after CRPC.

引用

页码：E1091 / E1098

页数：8

共 50 条

[31] Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer
Botchorishvili, George
Matikainen, Mika P.
Lilja, Hans
CURRENT OPINION IN UROLOGY, 2009, 19 (03) : 221 - 226
[32] Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy
Stangl-Kremser, Judith
Sun, Michael
Ho, Benedict
Thomas, Joseph
Nauseef, Jones. T. T.
Osborne, Joseph. R. R.
Molina, Ana
Sternberg, Cora. N. N.
Nanus, David. M. M.
Bander, Neil. H. H.
Tagawa, Scott
PROSTATE, 2023, 83 (14) : 1351 - 1357
[33] Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
Gafita, Andrei
Heck, Matthias M.
Rauscher, Isabel
Tauber, Robert
Cala, Lisena
Franz, Charlott
D'Alessandria, Calogero
Retz, Margitta
Weber, Wolfgang A.
Eiber, Matthias
JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (10) : 1476 - 1483
[34] Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics
Brady-Nicholls, Renee
Zhang, Jingsong
Zhang, Tian
Wang, Andrew Z.
Butler, Robert
Gatenby, Robert A.
Enderling, Heiko
NEOPLASIA, 2021, 23 (09): : 851 - 858
[35] Prostate-Specific Antigen Kinetics under Androgen Deprivation Therapy and Prostate Cancer Prognosis
Zhang, Li-min
Jiang, Hao-wen
Tong, Shi-jun
Zhu, Hui-qing
Liu, Jun
Ding, Qiang
UROLOGIA INTERNATIONALIS, 2013, 91 (01) : 38 - 48
[36] Prostate-specific Antigen Testing and Prostate Cancer Screening
Djavan, Bob
Eckersberger, Elisabeth
Finkelstein, Julia
Sadri, Helen
Taneja, Samir S.
Lepor, Herbert
PRIMARY CARE, 2010, 37 (03): : 441 - +
[37] Biomarkers for prostate cancer: prostate-specific antigen and beyond
Duffy, Michael J.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (03) : 326 - 339
[38] Complexed prostate-specific antigen for the detection of prostate cancer
Filella, X
Truan, D
Alcover, J
Gutierrez, R
Molina, R
Coca, F
Ballesta, AM
ANTICANCER RESEARCH, 2004, 24 (06) : 4181 - 4185
[39] Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Hwang, Taewon
Oh, Hyungseok
Lee, Jung Ah
Kim, Eo Jin
BMC UROLOGY, 2023, 23 (01)
[40] Prostate-Specific Membrane Antigen Expression on PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
Calderoni, Letizia
Maietti, Elisa
Farolfi, Andrea
Mei, Riccardo
Louie, Karly S.
Groaning, Michael
Fanti, Stefano
JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (06) : 910 - 917

← 1 2 3 4 5 →